Drugs /
dp303c
Overview
Clinical Trials
Dp303c has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dp303c, 1 is phase 1 (1 open).
ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for dp303c clinical trials.
Malignant solid tumor is the most common disease being investigated in dp303c clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.